首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

2104493

全球KIF18A標靶治療：臨床創新、聯合治療策略、治療方法、技術平台和臨床試驗的見解（2026年）

Global KIF18A Targeting Therapies Clinical Innovation, Combination Treatment Strategies, Therapeutic Approaches, Technology Platforms & Clinical Trials Insight 2026

出版日期: 2026年08月01日 | 出版商:

KuicK Research | 英文 90 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

《全球KIF18A標靶治療 - 臨床創新、聯合治療策略、治療方法、技術平台和臨床試驗（2026年）》報告的主要發現和亮點：

預計到2032年，首批針對 KIF18A 的商業化療法將問世。
臨床試驗的最高階段：I/II期
臨床試驗中針對 KIF18A的標靶治療的最新進展：超過20 種治療方法
依公司、國家、適應症和臨床試驗階段分類的KIF18A標靶治療的臨床試驗見解。
針對KIF18A的治療方法
公司特定開發技術平台概述
競爭格局

KIF18A標靶療法的必要性及本報告的意義

隨著對染色體不穩定性（CIN）認知的不斷深入，KIF18A標靶療法已成為精準醫學領域發展最快的方向之一，為癌症治療提供了一個潛在的藥物標靶。 KIF18A是一種有絲分裂馬達蛋白，在細胞分裂過程中輔助染色體排列和紡錘體組織。正常細胞可以透過其他途徑增殖，但KIF18A對於CIN陽性癌細胞完成細胞週期非常重要。正是由於這種對KIF18A的依賴性，使其成為開發針對多種實體瘤（包括高級別漿液性卵巢癌（HGSOC）、三陰性乳癌（TNBC）、結直腸癌和肺癌）標靶治療的理想合成固體癌。

與大多數針對分裂細胞的傳統細胞毒性藥物不同，KIF18A抑制劑利用癌細胞的脆弱性，這些脆弱性以染色體異常和基因組不穩定性增加為特徵。抑制KIF18A會透過導致染色體錯位和細胞週期阻斷延長來破壞有絲分裂，最終導致癌細胞死亡。這種方法加速標靶小分子抑制劑和其他新型療法的研發，目的是最佳化治療精準度，並為抗藥性癌症患者拓展治療選擇。

本報告全面概述了KIF18A標靶療法的現狀，包括其科學背景、治療方法、技術平台、臨床開發最新趨勢、市場前景、競爭格局以及未來的商業化機會。報告還涵蓋了KIF18A在腫瘤生物學中的作用、藥物研發策略以及針對多種癌症的最新研究進展。本報告為製藥公司、生技公司、投資者、科學家和其他相關人員提供了寶貴的訊息，幫助他們了解競爭格局，並把握這一新興治療領域的發展機會。

報告中包含對臨床試驗的深入分析

臨床開發將在決定KIF18A標靶治療市場的未來方面發揮關鍵作用。目前，多個實驗性藥物開發計畫正處於早期臨床階段。本報告分析了針對固體癌腫瘤（如高級別漿液性卵巢癌、乳癌、結直腸癌、肺癌以及其他染色體不穩定的惡性腫瘤）的KIF18A抑制劑的臨床試驗。目前，一些口服小分子KIF18A抑制劑已進入臨床研發階段，包括sovilnesib、orvanesib（VLS-1488）、ATX-295和MEN2501。

本報告概述了這些項目臨床開發的最新趨勢，並根據公司、適應症、地區、臨床試驗階段、患者群體類型和監管事件等標準進行了分析。除了關注單一藥物治療外，人們也越來越關注KIF18A抑制劑、微管抑制劑、化療和其他標靶治療的聯合治療概念。此類方法有望提高治療效果，並將KIF18A抑制劑療法的適用範圍擴大到更廣泛的患者群體。

領先的公司開發針對KIF18A的治療藥物

許多生技和製藥公司正利用染色體不穩定性（CIN）的生物學特性，在開發新型療法領域進行創新措施。 Volastra Therapeutics 是該領域的主要參與者之一，其產品組合包括 Sovilnesib 和 VLS-1488 等 KIF18A 抑制劑。該公司採用生物標記主導的開發策略，篩選 KIF18A 依賴性腫瘤患者。

Accent Therapeutics公司開發口服KIF18A抑制劑ATX-295，用於治療CIN陽性固體癌，目前進行針對晚期癌症的臨床評估。 Insilico Medicine公司也推動KIF18A抑制劑MEN2501的臨床試驗，不斷擴大其競爭優勢。Amgen、Aurigene Oncology和Tailor Bio等公司也在該領域的研究和開發中做出了各自獨特的貢獻。

技術平台、合作夥伴關係和協議

技術進步正推動KIF18A標靶療法的研發。例如，Volastra Therapeutics的「CINtech」平台是一種創新方法，它利用對染色體不穩定性（CIN）生物學的深入了解，發現癌症中的合成致死目標。透過這項技術，Volastra Therapeutics發現，高CIN水準的癌症高度依賴染色體排列機制，包括KIF18A。因此，與正常細胞相比，這類癌症被認為對KIF18A抑制劑極為敏感。此策略將有助於開發針對高染色體不穩定性腫瘤的選擇性KIF18A抑制劑，實現基於生物標記的治療方法。

戰略合作與授權交易也將在市場擴張中發揮關鍵作用。去年，Insilico Medicine將其極具前景的抗癌藥物MEN2501授權給Menarini Group旗下的Stemline Therapeutics，合約金額超過5.5億美元。該計畫目前正處於I期臨床試驗階段，反映出市場對KIF18A標靶療法的商業性興趣日益濃厚。

概述KIF18A標靶治療未來方向的報告

未來，KIF18A標靶療法的研發重點預計將放在擴大臨床應用範圍、基於生物標記最佳化患者篩選以及探索聯合治療。染色體不穩定性（CIN）譜分析、全基因組重複評估以及基於Rb通路生物標記的研究進展將有助於更有效地識別可能從治療中獲益的患者群體。

目前，多種KIF18A標靶藥物進行臨床試驗，隨著KIF18A標靶治療在腫瘤學各領域療效的證據不斷積累，其商業性價值日益凸顯。在小分子藥物設計、臨床試驗管理以及其他策略合作方面的持續研發進展，將進一步提升該療法的療效，並使其在不久的將來成為癌症精準治療的關鍵要素。

First KIF18A Targeting Therapy Commercial Availability Expected By 2032
Highest Phase Of Clinical Trials: Phase-I/II
Insight On KIF18A Targeting Therapies In Clinical Trials: > 20 Therapies
KIF18A Targeting Therapies Clinical Trials Insight By Company, Country, Indication and Phase
Therapeutic Approaches Targeting KIF18A
Development Technology Platforms Insight By companies
Competitive Landscape

Need For KIF18A Targeting Therapies & Why This Report?

Therapies targeting KIF18A have emerged as one of the fastest developing areas in the realm of precision medicine, thanks to growing understanding of chromosomal instability (CIN) as a potential drug target in oncology. KIF18A is a mitotic motor protein, which has a function of assisting in chromosome alignment and organizing the spindle apparatus during cell division. Even though normal cells are able to proliferate using different pathways, KIF18A is indispensable for the completion of the cell cycle in CIN-positive tumor cells. The dependence on KIF18A is what made the protein an appealing synthetic lethal target in the development of targeted therapies for various solid tumors such as high-grade serous ovarian cancer (HGSOC), triple negative breast cancer (TNBC), colorectal cancer, and lung cancer.

As opposed to the majority of conventional cytotoxic drugs targeting dividing cells, inhibitors of KIF18A take advantage of the weaknesses in tumor cells that are characterized by an abnormal number of chromosomes and increased genomic instability. Inhibition of KIF18A leads to disturbances in mitosis by causing chromosome misalignment, prolonged cell cycle arrest, and ultimately cancer cell death. This method has facilitated the development of targeted small molecule inhibitors and other novel therapeutic interventions designed to optimize the level of therapeutic precision and increase the treatment options for patients with resistant cancers.

This report offers a thorough review of the KIF18A-targeted therapies landscape including the scientific background, therapeutic approaches, technology platforms, current trends in clinical development, market perspectives, competitive intelligence and future opportunities for commercialization of this area. The report covers the involvement of KIF18A in tumor biology, drug discovery strategies and recent research in different types of cancers. It provides valuable information for pharmaceutical companies, biotech firms, investors, scientists and other stakeholders in order to understand the competitive landscape and discover the opportunities in this developing therapeutic area.

Clinical Trials Insight Included In Report

Clinical development will play a crucial role in defining the future of the KIF18A targeting therapy market, with several experimental drug development projects being evaluated in early clinical stages. The report offers an analysis of clinical trials of KIF18A inhibitors among solid tumors such as HGSOC, breast cancer, colorectal cancer, lung cancer, and other chromosomally unstable malignancies. Currently, there are clinical pipeline programs featuring oral small molecule inhibitors of KIF18A such as sovilnesib, orvanesib (VLS-1488), ATX-295, and MEN2501.

This report outlines current trends in the clinical development of these programs based on criteria such as company, indication, geography, phase, type of patient population, and regulatory events. Besides the focus on monotherapies, there is growing interest in combination therapy concepts, which include combinations of KIF18A inhibitors with microtubule inhibitors, chemotherapy, and other targeted medicines. Such an approach may improve therapeutic effects and extend the use of KIF18A inhibition to wider patient groups.

Major Companies Developing KIF18A Targeting Therapies

There are many biotech and pharmaceutical firms engaged in innovative work in the domain of exploiting the biology of CINs to develop new therapeutics. Volastra Therapeutics can be regarded as the major player in this area, with its portfolio of KIF18A inhibitors like sovilnesib and VLS-1488. The firm develops the strategy of biomarker-driven development to select patients with KIF18A-dependent tumors.

Accent Therapeutics is developing ATX-295, an oral KIF18A inhibitor indicated for CIN-positive solid tumors and currently under clinical evaluation in advanced cancers. Insilico Medicine, too, through MEN2501, continues to expand its competitive advantage with the development of a KIF18A inhibitor into clinical trials. There are other companies, such as Amgen, Aurigene Oncology, and Tailor Bio, making their own contributions in research and development within this field.

Technology Platforms, Collaborations & Agreements

Technological advancement is making it possible for there to be advances made in the development of therapies that target KIF18A. For instance, the CINtech platform by Volastra Therapeutics is an innovative way that utilizes the knowledge gained about chromosomal instability (CIN) biology to discover synthetic lethal targets in cancer. Through this technology, Volastra Therapeutics was able to determine that CIN-high cancers were highly dependent on chromosome alignment machinery, which included KIF18A. Therefore, such types of cancers would be highly vulnerable to KIF18A inhibitors in contrast to healthy cells. This strategy would enable development of selective KIF18A inhibitors to address high chromosomal instability tumors and would allow for biomarker directed therapeutic approaches.

Strategic partnerships and licensing deals would also play a role in market expansion. In the last year, Insilico Medicine licensed their promising cancer treatment MEN2501 to Stemline Therapeutics, which is part of the Menarini Group, under a deal more than US$ 550 Million. This program has now advanced to Phase I clinical trials, reflecting the increasing commercial interest in targeting KIF18A.

Report Indicating Future Direction Of KIF18A Targeting Therapies

Going forward, the KIF18A targeting therapy pipeline is anticipated to focus on the broadening of clinical use application, refinement of biomarker-led patient selection and investigation of combination therapy. Progress in CIN profiling, the estimation of whole-genome doubling and Rb-pathway-led biomarkers is likely to contribute to more efficient targeting of those patient groups most apt to respond.

The commercial relevance for KIF18A targeting treatments is growing now as several KIF18A agents make their way through clinical trials, ultimately broadening evidence for use as a viable target across the field of oncology. Continued R&D advancements regarding the small molecule design, trial management as well as other strategic collaborations are to bolster this therapeutic modality further to where it becomes a critical element in precision medicine in the context of cancer therapies in the coming time frame.

1. Research Methodology

2. Introduction To KIF18A Targeting Therapies

2.1 Overview Of Kinesin Family & KIF18A
2.2 History & Development

3. Scientific & Biological Background

3.1 Overview Of KIF18A
3.2 Oncogenic Role & Therapeutic Rationale

4. Therapeutic Approaches Targeting KIF18A

4.1 Small Molecule Inhibitors
4.2 RNAi Based Strategies

5. KIF18A Targeting Therapies R&D Trends By Indication

5.1 Solid Tumors
5.2 Hematological Malignancies

6. KIF18A Targeting Therapies Combination Strategies By Drug Class

7. KIF18A Targeting Therapies Market Potential Overview

7.1 Current Scenario
7.2 Future R&D & Commercial Opportunities

8. KIF18A Targeting Therapies Development Technology Platforms

9. KIF18A Targeting Therapies Clinical Trials Overview

9.1 By Phase
9.2 By Country
9.3 By Company
9.4 By Indication
9.5 By Priority Status

10. KIF18A Targeting Therapies Clinical Trials Insight By Company, Indication & Phase

10.1 Research
10.2 Preclinical
10.3 Phase I
10.4 Phase I/II

11. KIF18A Targeting Therapies Market Dynamics

11.1 Drivers & Opportunities
11.2 Challenges & Restraints

12. Competitive Landscape

12.1 Accent Therapeutics
12.2 Amgen
12.3 Apeiron Therapeutics
12.4 Aurigene Oncology
12.5 Genhouse Bio
12.6 GeneScience Pharmaceuticals
12.7 Iambic Therapeutics
12.8 Innogate Pharma
12.9 Insilico Medicine
12.10 Satya Pharma
12.11 Tailor Bio
12.12 Volastra

簡介目錄圖表

List of Figures

Figure 2-1: Kinesin Family Overview
Figure 2-2: KIF18A - Overview
Figure 2-3: KIF18A Research - Discovery & Evolution
Figure 3-1: KIF18A - Role In Mitosis
Figure 3-2: KIF18A - Expression In Normal & Cancer Tissues
Figure 3-3: KIF18A As Therapeutic Target In Cancer
Figure 3-4: KIF18A - Synthetic Lethality Pathway
Figure 3-5: KIF18A As Prognostic Marker In Cancer
Figure 4-1: Small Molecule KIF18A Inhibitors - Mechanism Of Action
Figure 4-2: RNAi-Mediated Silencing Of KIF18A - Mechanism Of Action
Figure 4-3: KIF18A RNAi - Effects On Tumor Cell Phenotypes
Figure 5-1: SOVI-2302 Phase 1 (NCT06084416) Study - Initiation & Completion Year
Figure 5-2: VLS-1488-2201 Phase 1/2 (NCT05902988) Study - Initiation & Completion Year
Figure 5-3: ATX-295-001 Phase 1/2 (NCT06799065) Study - Initiation & Completion Year
Figure 5-4: GH2616-101 Phase 1 (NCT06329206) Study - Initiation & Completion Year
Figure 5-5: KIF18A In Hematological Malignancies - Role & Therapeutic Opportunity
Figure 7-1: KIF18A Targeting Therapies - Future Opportunities
Figure 8-1: Chemistry42 - Insilico Medicine
Figure 8-2: CINtech Platform - Volastra Therapeutics
Figure 8-3: Unnamed Platform - Accent Therapeutics
Figure 8-4: Chromosomal Instability Platform - Tailor Bio
Figure 9-1: Global - Number Of KF18A Targeting Therapies In Clinical Trials By Phase, 2026
Figure 9-2: Global - Number Of KF18A Targeting Therapies In Clinical Trials By Country, 2026
Figure 9-3: Global - Number Of KF18A Targeting Therapies In Clinical Trials By Company, 2026
Figure 9-4: Global - Number Of KF18A Targeting Therapies In Clinical Trials By Indication, 2026
Figure 9-5: Global - Number Of KF18A Targeting Therapies In Clinical Trials By Priority Status, 2026
Figure 11-1: KIF18A Targeting Therapies Market - Drivers & Opportunities
Figure 11-2: KIF18A Targeting Therapies Market - Challenges & Restraints